Cite

    Richard L Wasserman et al.. “Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.” Immunotherapy, vol. 8, n.d., pp. 1175–1186. http://access.bl.uk/ark:/81055/vdc_100150250360.0x00000f